Sulforaphane supplement to protect the heart during doxorubicin
Part of Heart & circulation, Injuries & trauma clinical trials.
This trial tests whether a nutritional supplement called sulforaphane (SFN) can help protect heart function in people with breast cancer who are receiving doxorubicin (a chemotherapy that can affect the heart). Participants take caplets and have heart and safety monitoring to see if the supplement reduces heart-related side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 18 to 89
- Have breast cancer that will be treated with a doxorubicin-containing chemotherapy plan
- Be able to take the study caplets (up to 8 per day)
- If you can become pregnant (typically ages 18–50), agree to use birth control during the study
- You should not have had coronary, carotid, or peripheral artery disease
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a daily pill called dapagliflozin can help protect the heart from damage caused by doxorubicin chemotherapy in people being treated for early-stage breast cancer. If you are starting doxorubicin and have a healthy heart, this might lower your risk of heart problems later.
This trial tests whether a specific nutrition supplement (amino acids and flavonoids) can lessen chemotherapy side effects, support nutrition, and improve quality of life in people with non-metastatic breast cancer. It focuses on women who are receiving certain chemotherapy medicines and can eat by mouth and attend regular visits.
This study tests whether a natural supplement made from grape polyphenols can help protect the heart from damage caused by certain breast cancer chemotherapy drugs. It aims to see if taking this supplement alongside treatment can reduce the risk of heart problems.
This trial checks how well the heart handles anthracycline chemotherapy in breast cancer patients. It helps doctors find early signs of heart side effects so they can keep you safe during treatment.
This trial tests whether taking linagliptin, a diabetes medicine, can help protect the heart during chemotherapy with doxorubicin. It might reduce the risk of heart damage caused by this chemo drug.
This trial tests whether two different diabetes drugs (SGLT-2 inhibitors and DPP-4 inhibitors) can help prevent heart damage that anthracycline chemotherapy can cause in breast cancer patients. You would receive one of the two drugs during your treatment to see if it protects your heart.
Hear when a new Anthracycline Related Cardiotoxicity in Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.